HVTN 122: A phase 1 double-blind randomized clinical trial to evaluate the safety and immunogenicity of a recombinant oligomeric gp145 clade C Env protein (gp145 C.6980) in healthy HIV-1uninfected adult participants in the US
-
- STATUS
- None
Updated on 19 February 2024
Summary
This is a multi-center, randomized, placebo controlled, double blind trial to evaluate the safety and tolerability of 1 injection of gp145 C.6980 at 2 dose levels with alum adjuvant in HIV-seronegative low risk adults.45 healthy, HIV-1uninfected volunteers aged 18 to 50 years: 40 vaccinees, 5 placebo recipients in the US will be enrolled. There are three arms: Group 1 (25) will receive 300 mcg gp145 and Group 2 (15) will receive 100 mcg gp145 and Group 3 (5) will receive placebo.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.